Literature DB >> 9593404

Optimism over vaccines administered via mucosal surfaces.

M M Levine1, G Dougan.   

Abstract

Mesh：

Substances：

Year:  1998        PMID： 9593404     DOI： 10.1016/S0140-6736(05)79439-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  21 in total

1.  Vaccines against gut pathogens.

Authors:  P Mastroeni; F Bowe; R Cahill; C Simmons; G Dougan
Journal:  Gut       Date:  1999-11       Impact factor: 23.059

Review 2.  The immune responses to bacterial antigens encountered in vivo at mucosal surfaces.

Authors:  G Dougan; M Ghaem-Maghami; D Pickard; G Frankel; G Douce; S Clare; S Dunstan; C Simmons
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-05-29       Impact factor: 6.237

Review 3.  The development and use of vaccine adjuvants.

Authors:  Robert Edelman
Journal:  Mol Biotechnol       Date:  2002-06       Impact factor: 2.695

Review 4.  Recent advances in vaccine adjuvants.

Authors:  Manmohan Singh; Derek T O'Hagan
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

Review 5.  Recent progress in mucosal vaccine development: potential and limitations.

Authors:  Nils Lycke
Journal:  Nat Rev Immunol       Date:  2012-07-25       Impact factor: 53.106

6.  Protein-loaded emulsion electrospun fibers optimized for bioactivity retention and pH-controlled release for peroral delivery of biologic therapeutics.

Authors:  Hannah Frizzell; Tiffany J Ohlsen; Kim A Woodrow
Journal:  Int J Pharm       Date:  2017-09-21       Impact factor: 5.875

7.  Construction of a recombinant allergen-producing probiotic bacterial strain: Introduction of a new line for a live oral vaccine against Chenopodium album pollen allergy.

Authors:  Leila Roozbeh Nasiraie; Farideh Tabatabaie; Mojtaba Sankian; Fakhri Shahidi; Abdolreza Varasteh
Journal:  Rep Biochem Mol Biol       Date:  2013-10

Review 8.  Current state and challenges in developing oral vaccines.

Authors:  Julia E Vela Ramirez; Lindsey A Sharpe; Nicholas A Peppas
Journal:  Adv Drug Deliv Rev       Date:  2017-04-22       Impact factor: 15.470

9.  Heterologous production of human papillomavirus type-16 L1 protein by a lactic acid bacterium.

Authors:  Naima G Cortes-Perez; Pascale Kharrat; Philippe Langella; Luis G Bermúdez-Humarán
Journal:  BMC Res Notes       Date:  2009-08-24

10.  Recombinant porcine rotavirus VP4 and VP4-LTB expressed in Lactobacillus casei induced mucosal and systemic antibody responses in mice.

Authors:  Xinyuan Qiao; Guiwei Li; Xiangqing Wang; Xiaojing Li; Min Liu; Yijing Li
Journal:  BMC Microbiol       Date:  2009-12-04       Impact factor: 3.605
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.